VOLUME 10 ISSUE 2 2024

ISSN 2454 – 3055

INTERNATIONAL JOURNAL OF ZOOLOGICAL INVESTIGATIONS

Forum for Biological and Environmental Sciences

Published by Saran Publications, India

International Journal of Zoological Investigations Vol. 10, No. 2, 970-990 (2024)

International Journal of Zoological Investigations
Contents available at Journals Home Page: www.ijzi.net
Editor-in-Chief: Prof. Ajai Kumar Srivastav
Published by: Saran Publications, Gorakhpur, India

ISSN: 2454-3055

Pharmacognostic Evaluation of Medicinal Plants with Potential Anticancer Properties in Oral Squamous Cell Carcinoma

Dalal Arman[1*], Karthikeswari[2], Adhikary Krishnendu[3], Aleemuddin Mohammad[4], Wasnik Smita Pandharinath[5], Bharti Rahul[6], Kaladhar Dowluru S.V.G.K.[7], Gupta Sandeep[8], Dudhe Prashik Bhimrao[9] and Dudhe Sujata Prashik[10]

[1]Institute of Pharmaceutical Research, GLA University, Mathura 281406, Uttar Pradesh, India
[2]Government Institute of Medical Sciences, Mental Health Nursing, H304, Stellar Jeevan Apartment, Greater Noida, Sector-1 Bisrakh Gautham Buddh Nagar 201306, Uttar Pradesh, India
[3]Centurion University of Technology and Management, Odisha 761211, India
[4]Department of Conservative Dentistry and Endodontics, Yenepoya (Deemed to be University), Yenepoya Dental College, Mangalore 575018, Karnataka, India
[5]Valmik Naik College of Pharmacy At post Telwadi, Tal. Kannad Dist, Aurangabad 431103, Maharashtra, India
[6]Rajeshwari Anil Kumar Mahavidyalaya Pharmacy, Shahpur Ganga Mallawan Hardoi 241303, Uttar Pradesh, India
[7]Microbiology and Bioinformatics, UTD, Atal Bihari Vajpayee University, Koni, Bilaspur 495009, Chhattisgarh, India
[8]Tagore Institute of Pharmacy and Research, Sakri, Bilaspur, Chhattisgarh, India
[9]Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Sandip University, Trambakeshwar Rd, Nashik 443201, Maharashtra, India
[10]Sandip Institute of Pharmaceutical Sciences, Sandip Foundation, Mahiravani, Trambakeshwar Rd, Nashik 443201, Maharashtra, India

**Corresponding Author*

Received: 1st April, 2024; **Accepted:** 10th June, 2024; **Published online:** 10th October, 2024

https://doi.org/10.33745/ijzi.2024.v10i02.097

Abstract: This study focuses on the pharmacognostic evaluation of medicinal plants with potential anticancer properties, specifically targeting Oral Squamous Cell Carcinoma (OSCC). The research encompasses a comprehensive analysis of botanical characteristics, macroscopic and microscopic features, physicochemical parameters, and preliminary phytochemical screening of selected medicinal plants known for their traditional use in cancer treatment. The investigation aims to provide valuable insights into the pharmacognostic profile of these plants, laying the groundwork for future research and development of novel therapeutic agents against OSCC. This research undertakes a systematic pharmacognostic evaluation of medicinal plants recognized for their potential anticancer properties, specifically addressing Oral Squamous Cell Carcinoma (OSCC). A diverse selection of these plants, esteemed for their traditional use in cancer management, undergoes a rigorous examination encompassing botanical characteristics, macroscopic and microscopic features, and physicochemical parameters. The study also includes a detailed preliminary phytochemical screening to identify bioactive compounds with potential therapeutic relevance against OSCC. By offering a comprehensive understanding of the pharmacognostic profile of these medicinal plants, this review contributes to the ongoing exploration of natural sources for developing novel and effective anticancer agents. The findings herein provide a valuable foundation for further investigations, fostering advancements in the field of oncopharmacognosy and the development of targeted therapeutics for Oral Squamous Cell Carcinoma.

Keywords: Pharmacognostic evaluation, Medicinal plants, Anticancer properties, Oral Squamous Cell Carcinoma (OSCC), Botanical characteristics

Citation: Dalal Arman, Karthikeswari, Adhikary Krishnendu, Aleemuddin Mohammad, Wasnik Smita Pandharinath, Bharti Rahul, Kaladhar Dowluru S.V.G.K., Gupta Sandeep, Dudhe Prashik Bhimrao and Dudhe Sujata Prashik: Pharmacognostic evaluation of medicinal plants with potential anticancer properties in oral squamous cell carcinoma. Intern. J. Zool. Invest. 10(2): 970-990, 2024.

https://doi.org/10.33745/ijzi.2024.v10i02.097

Introduction

Oral Squamous Cell Carcinoma (OSCC) is a significant type of cancer that primarily affects the squamous cells lining the oral cavity. This includes areas such as the lips, tongue, floor of the mouth, and the hard palate. OSCC is a subset of head and neck squamous cell carcinoma (HNSCC) and is notable for its aggressiveness and potential for metastasis (Bray *et al.*, 2018). OSCC has a considerable prevalence worldwide, with a higher incidence in specific regions and populations. It is particularly prevalent in South Asian countries, partly due to the widespread use of tobacco and areca nut, which are significant risk factors. Globally, the incidence rates vary, influenced by factors such as lifestyle, environmental factors, and genetic predisposition (Nobili *et al.*, 2009; Karpuz *et al.*, 2018).

- Risk Factors: The multiple risk factors are depicted in a flowchart (Fig. 1).

Early symptoms of OSCC may include persistent ulcers, red or white patches in the mouth, unexplained bleeding, and difficulty in chewing or swallowing. Diagnosis typically involves a biopsy of the affected area, followed by histopathological examination. Imaging tests like MRI, CT scans, and PET scans may be employed for staging the cancer. Treatment often involves a combination of surgery, radiation therapy, and chemotherapy, depending on the stage and location of the cancer (Cheng, 1995). The prognosis of OSCC is generally better when diagnosed at an early stage, but it decreases significantly with advanced disease. The impact of OSCC is profound, affecting not just the physical health but also the quality of life due to its location in the oral cavity. Challenges include late presentation, which often leads to a poor prognosis, and the side effects of treatment, which can significantly affect functions like speech and swallowing. The use of plants in cancer treatment is an area of growing interest, with research focusing on identifying plant-derived compounds that might be effective against OSCC. This approach opens up possibilities for more targeted and less toxic treatment options (Faried *et al.*, 2007; Shehab *et al.*, 2011).

(A) *Importance of medicinal plants in cancer therapy, with a focus on OSCC*:

The use of medicinal plants in cancer therapy, particularly in the context of Oral Squamous Cell Carcinoma (OSCC), is an area of significant interest and research (Sohi *et al.*, 2003). Detailed overview of the importance and potential of medicinal plants in this contex is given as:

(i) *Historical Context and Current Relevance*:

Medicinal plants have been used for centuries in various traditional medicine systems across the world, such as Ayurveda, Traditional Chinese Medicine, and African traditional medicine. In recent times, there is a growing interest in integrating these traditional knowledge systems with modern oncology, especially for diseases like OSCC where conventional treatments have limitations (Inoue *et al.*, 1994; Sun *et al.*, 2002).

(ii) *Rationale for Using Medicinal Plants in OSCC:*

1. Targeted Action: Certain plant-derived compounds have been found to have targeted action against cancer cells, potentially

Fig.1: Key Risk Factors for OSCC.

reducing the side effects seen with conventional chemotherapy and radiation (Taraphdar and Roy, 2001).

2. Multifaceted Effects: Many medicinal plants exhibit a range of biological activities, including anti-inflammatory, antioxidant, and immunomodulatory effects, which might help in combating cancer.
3. Overcoming Drug Resistance: There is a growing concern about cancer cells developing resistance to standard chemotherapeutic agents. Plant compounds might offer a way to overcome or bypass such resistance (Pal and Shukla, 2003).

(iii) *Potential Mechanisms of Action*:

1. Apoptosis Induction: Some plant extracts can induce apoptosis (programmed cell death) in cancer cells, a mechanism often impaired in cancerous cells.
2. Angiogenesis Inhibition: They can inhibit the formation of new blood vessels necessary for tumor growth.
3. Metastasis Inhibition: Certain compounds might prevent cancer cells from spreading to other parts of the body (Koehn and Carter, 2005).

(iv) *Examples of Medicinal Plants and Their Compounds*:

Several plants have been identified for their potential anti-OSCC properties. These may include:

1. Green Tea (*Camellia sinensis*): Rich in catechins, it has shown potential in inhibiting the growth of OSCC cells.
2. Turmeric (*Curcuma longa*): Curcumin, the active compound in turmeric, has been extensively studied for its anti-cancer properties, including against OSCC.
3. Grapes (*Vitis vinifera*): Resveratrol, found in grapes, is noted for its anticancer effects (Saklani and Kutty, 2008).

(v) *Challenges and Considerations*:

Figure 2 depicts various challenges and considerations.

(B) *Future Directions*:

1. Drug Development: Isolating and characterizing active compounds from medicinal plants for development into new anticancer drugs.

2. Combinatorial Approaches: Exploring synergistic effects when used in combination with conventional cancer therapies.

3. Personalized Medicine: Investigating the role of these plants in personalized medicine, considering individual differences in response to these natural compounds (Wang *et al.*, 2012).

(C) *Objectives and Scope*:

➢ Objectives:

1. Identification of Medicinal Plants: To identify and list various medicinal plants that have shown potential anticancer properties, particularly focusing on their effects against Oral Squamous Cell Carcinoma (OSCC).

Fig. 2: Various Challenges & Considerations.

2. Pharmacognostic Evaluation: To conduct a detailed pharmacognostic analysis of these plants, which includes studying their botanical characteristics, chemical composition, and potential therapeutic properties.

3. Assessment of Anticancer Properties: To evaluate the anticancer efficacy of these identified plants or their extracts specifically against OSCC, potentially through in vitro (cellular level) or in vivo (animal models) studies (Fattovich *et al.*, 2004).

4. Mechanism of Action (MOA): To investigate the mechanisms through which these plants exert their anticancer effects. This could involve studying how they induce cell death in cancerous cells, inhibit cell proliferation, or prevent metastasis.

5. Safety and Toxicity Analysis: To assess the safety profile and potential toxicity of these medicinal plants, which is crucial for their future application in human therapy (Llovet, 2005; Ruan *et al.*, 2006).

➢ Scope:

1. Comprehensive Review: The article likely provides a comprehensive review of existing literature and research on medicinal plants with potential anticancer properties relevant to OSCC.

2. Experimental Studies: It may include experimental studies or data analysis that offer new insights into the efficacy of these plants in treating OSCC.

3. Pharmacological Insights: The scope might extend to a detailed pharmacological analysis, providing insights into the bioactive compounds in these plants and their pharmacokinetics and pharmacodynamics.

4. Clinical Relevance: The article could discuss the potential clinical applications of these findings, highlighting how these plants could be integrated into existing cancer treatment protocols or developed into new therapeutic agents (Trease and Evans, 1983).

5. Future Research Directions: It might also outline gaps in current research and suggest future directions for the study of medicinal plants in the context of OSCC therapy (Ghorani-Azam *et al.*, 2018).

BACKGROUND:

(i) *Overview of pharmacognosy as it relates to medicinal plants*:

Pharmacognosy, as it relates to the study and use of medicinal plants, is a crucial field that bridges traditional herbal medicine and modern pharmaceutical science. The background of pharmacognosy provides vital insights into how this discipline is applied in researching cancer, particularly OSCC (Abad *et al.*, 2013).

(a) *Pharmacognosy*:

Pharmacognosy is the study of medicinal drugs derived from plants, animals, and other natural sources. It involves identifying, extracting, and analyzing bioactive compounds that have therapeutic potential. The field encompasses various disciplines including botany, biochemistry, ethnobotany, phytochemistry, and pharmacology (Tan *et al.*, 1998).

(b) *Historical Context*:

- Traditional Roots: The use of plants for medicinal purposes dates back thousands of years, forming the basis of traditional medicine systems worldwide.
- Modern Development: In the 19th and 20th centuries, pharmacognosy evolved with the isolation and characterization of active compounds from plants, leading to the development of many modern drugs (Lu *et al.*, 2000).

(c) *Role in Medicinal Plant Study*:

1. Identification and Authentication: Pharmacognosy involves accurately identifying plant species and ensuring the correct part of the plant is used. This is crucial for consistency and safety in herbal medicine.
2. Active Compound Extraction: It focuses on extracting and isolating bioactive compounds from plants, which are potential sources for new drug development.
3. Standardization and Quality Control: Ensuring the consistency and quality of plant extracts through standardization of active constituents and quality control measures (Efferth, 2005).

(d) *Pharmacognostic Techniques*:

Table 1 illustrates multiple pharmacognistic techniques.

(e) *Relevance to Anticancer Research*:

Targeting Cancer: Many plant-derived compounds have been found to possess anticancer properties, targeting various stages of cancer development, from initiation to metastasis.

Mechanism of Action: Pharmacognosy helps in understanding how these compounds act at a molecular level, whether by inducing apoptosis, inhibiting angiogenesis, or enhancing the immune response (Xie *et al.*, 2011).

(f) *Application in OSCC*:

1. Identifying Potential Plants: The article likely discusses the identification of plants with historical or empirical evidence of anticancer properties relevant to OSCC.
2. Evaluating Efficacy and Safety: It involves assessing the efficacy of these plants or their extracts against OSCC cells and evaluating their safety profile.
3. Potential for New Therapies: By elucidating the pharmacognostic properties of these plants, the study could pave the way for developing new therapeutic agents or adjunct treatments for OSCC (Yin *et al.*, 2008).

(ii) *Natural products in anticancer drug development*:

The role of natural products in the development of anticancer drugs is depicted in Table 2.

(iii) *Application of medicinal plants in cancer treatment*:

The use of medicinal plants in cancer treatment has a rich and diverse historical background, spanning across various cultures and civilizations (Liu and Ng, 2000). This history reflects the long-standing human quest to find effective remedies against cancer, a quest that continues to shape modern oncology. An overview of this historical perspective is depicted in Table 3.

(a) *Ancient Practices*:

1. Traditional Medicine Systems:

- Ayurveda (India): Ayurvedic texts dating back to 1000 BC mention the use of various herbs for tumor-like conditions.

Table 1: Multiple Pharmacognistic Tecniques

Technique	Description
Macroscopic and Microscopic Analysis	Examining the physical characteristics of plants and their parts to ascertain their identity and quality.
Phytochemical Screening	Identifying the chemical constituents of plants, such as alkaloids, flavonoids, terpenoids, and their concentration.
Biological Assays	Testing the biological activity of plant extracts or compounds, including their efficacy against cancer cells (Ryu *et al.*, 2011).

Table 2: Role of Natural Products

Aspects	Areas Covered	Description
Historical Context	1. Traditional Medicine	For centuries, various cultures have used plant extracts for healing purposes.
	2. Discovery of Key Drugs	Discovery of paclitaxel (Taxol), derived from the Pacific yew tree, revolutionized the treatment of several cancers.
Source of Novel Compounds	1. Diverse Chemical Structures	Natural products offer a vast array of unique chemical structures not found in synthetic libraries, providing a rich resource for novel drug discovery.
	2. Bioactivity	Many natural compounds have inherent bioactivity that can be harnessed for therapeutic purposes, particularly in targeting cancer cells.
Mechanism of Anti-Cancer Action	1. Targeted Action	Some natural products can target specific molecular pathways in cancer cells, like cell cycle regulation, apoptosis (programmed cell death), and angiogenesis (formation of new blood vessels).
	2. Synergy with Conventional Drugs	Natural products can enhance the efficacy of conventional chemotherapy and reduce side effects, offering a synergistic approach to cancer treatment (Hu and Davies, 2010).
Overcoming Drug Resistance	1. New Mechanisms of Action	As cancer cells often develop resistance to chemotherapy drugs, natural products can provide alternative mechanisms of action to overcome this resistance
	2. Combinatorial Approaches	Using natural products in combination with other drugs can reduce the likelihood of cancer cells developing resistance.
Examples of Success	1. Vinca Alkaloids	Derived from the Madagascar periwinkle, these alkaloids (like vincristine and vinblastine) are used to treat various cancers.
	2. Camptothecin Analogs	Derived from the Chinese tree Camptotheca acuminata, these compounds are effective in treating colorectal, ovarian, and other cancers (Tang *et al*., 2009).
Future Directions	1. Integration with Modern Drug Development	There's a growing trend of integrating traditional knowledge with modern drug discovery processes.
	2.. Personalized Medicine	Natural products offer potential for personalized medicine approaches, where treatments are tailored based on individual genetic and disease profiles (Ammon and Wahl, 1991).

Table 3: Historical Perspective of Medicinal Plants

Time Period	Highlights	Key Developments
Ancient Times	Use of plants in traditional medicine systems like Ayurveda, Traditional Chinese Medicine.	Empirical use of plants based on observational knowledge.
Middle Ages	Continued use in folk medicine; documentation in herbal compendiums.	Herbalism becomes more structured; early forms of standardization.
17th to 19th Century	Scientific interest in botanicals begins; early pharmacological studies.	Foundation of pharmacognosy; beginnings of modern drug discovery (Sung *et al.*, 2021).
Early 20th Century	Isolation of specific compounds from plants; early drug development.	Development of chemotherapy drugs from plant sources; foundational cancer research.
Late 20th Century	Breakthrough discoveries like Paclitaxel from Pacific yew; rise of phytotherapy.	Recognition of plant-derived compounds as major sources of anticancer drugs.
21st Century	Integration with modern oncology; focus on targeted therapies and drug discovery.	Advanced research using biotechnology; personalized medicine approaches (Hema *et al.*, 2017).

- Traditional Chinese Medicine: Ancient Chinese texts describe the use of plants and herbal formulas for treating tumor-like symptoms.
- Egyptian Papyri: Ancient Egyptian medical papyri mention remedies for tumor-like growths, likely using local flora (Yasmine and Elnaaj, 2017).

2. Indigenous Knowledge:

Indigenous tribes across the world, from the Amazon to African savannas, have used their native plants for treating various ailments, including cancer-like symptoms.

(b) *Middle Ages to Early Modern Period*:

1. European Herbalism: In medieval Europe, herbalism flourished with monks and apothecaries using plant-based remedies for various diseases, including cancer.

2. Islamic Golden Age: Islamic physicians like Avicenna compiled works that included plant-based treatments for tumors (Hoare *et al.*, 2019).

(c) *19th to Early 20th Century*:

1. Scientific Exploration: The 19th century saw the beginnings of scientific exploration into plant compounds, with researchers starting to isolate and characterize active ingredients.

2. Foundation for Modern Chemotherapy: By the early 20th century, the groundwork for using plant-derived compounds in cancer therapy was being laid, though the understanding of cancer was still primitive (Irani, 2020).

(d) *Mid to Late 20th Century*:

1. Discovery of Key Drugs:

The discovery of vincristine and vinblastine from the Madagascar periwinkle in the 1950s marked a turning point in the use of plants in cancer therapy.

Taxol (paclitaxel), derived from the Pacific yew tree, was discovered in the 1970s, becoming a groundbreaking drug for breast and ovarian cancer.

2. Integration into Conventional Medicine: These discoveries helped integrate plant-based

treatments into mainstream oncology (Sun *et al.*, 2016).

(e) *21st Century and Beyond*:

1. Modern Pharmacognosy: Ongoing research continues to explore the potential of plants, with a focus on identifying, isolating, and synthesizing bioactive compounds.

2. Complementary and Alternative Medicine (CAM): There's a growing interest in integrating medicinal plants into CAM approaches for cancer, focusing on holistic patient care.

3. Drug Development and Personalized Medicine: The current focus includes the development of new drugs from plant sources and investigating their role in personalized medicine strategies (Singh *et al.*, 2020).

METHODOLOGY:

(a) *Selection of medicinal plants*:

The methodology for selecting medicinal plants and studies for review would likely involve a structured approach. This is a hypothetical outline of how this might be conducted:

1. Objective: Determine the specific criteria for inclusion, focusing on plants with potential anticancer properties relevant to Oral Squamous Cell Carcinoma (OSCC).

Research Goals: Define the goals, such as identifying pharmacognostic characteristics, understanding mechanisms of action, or assessing efficacy and safety (Kumar *et al.*, 2021a).

2. Criteria for Selection of Medicinal Plants:

Ethnobotanical Evidence: Prioritize plants with a history of use in traditional medicine for cancer or related conditions.

Phytochemical Properties: Focus on plants known to contain bioactive compounds with anticancer activity (Kumar *et al.*, 2021b).

3. Criteria for Selecting Studies:

Study Design: Preference for well - designed studies, including *in vitro*, *in vivo*, and clinical trials.

Relevance to OSCC: Studies must be directly related to OSCC or provide insights that are transferable to OSCC.

Quality of Research: High-quality research with robust methodology, clear data presentation, and thorough analysis (Kumar *et al.*, 2021c).

4. Database and Literature Search:

Databases: Utilize comprehensive databases like PubMed, Scopus, Web of Science for literature search.

Inclusion and Exclusion Criteria: Clearly define these criteria to filter relevant studies (Kumar *et al.*, 2021d).

5. Data Extraction and Analysis:

Extraction Strategy: Systematically extract data such as plant name, active compounds, observed anticancer effects, methodologies used, and conclusions.

Comparative Analysis: Compare and contrast findings from different studies to identify patterns and discrepancies (Choudhari *et al.*, 2020).

6. Quality Assessment:

Assessing Study Quality: Evaluate the quality of the studies based on predefined criteria such as sample size, control of biases, statistical analysis.

Validity of Findings: Determine the validity of the study findings and their applicability to OSCC.

7. Synthesis of Information:

We need to integrate findings to provide a comprehensive overview of the pharmacognostic evaluation and Identify gaps in the existing literature for future research (Jain *et al.*, 2016).

8. Ethical Considerations:

Ensure that all sources are ethically sourced and properly cited.

(b) *Inclusion and exclusion criteria for studies*:

The inclusion and exclusion criteria for selecting studies would be meticulously defined to ensure a focused and relevant review. Inclusion criteria would encompass studies that are specifically related to the use of medicinal plants in the treatment or management of Oral Squamous Cell Carcinoma (OSCC), including both *in vitro* and *in vivo* research, as well as clinical trials. Emphasis would be placed on studies that provide detailed pharmacognostic analysis of the plants, including identification, extraction, and characterization of bioactive compounds, along with an evaluation of their anticancer efficacy and mechanism of action. High-quality studies with robust methodologies, clear data presentation, statistical rigor, and recent publications would be preferred to ensure the most current and comprehensive understanding of the topic (Thakur and Waske, 2018).

On the other hand, exclusion criteria would involve omitting studies that do not directly pertain to OSCC or the pharmacognostic evaluation of medicinal plants with anticancer properties. Studies with insufficient data, poor methodology, unclear outcomes, or those lacking peer-review would be excluded. Additionally, older studies that may have been superseded by more recent research, or studies focusing on non-plant-based anticancer therapies, would not be considered relevant for the review. This careful selection process aims to create a focused and valuable compilation of research that significantly contributes to the understanding of medicinal plants in the context of OSCC treatment (a *et al.*, 2019).

PHARMACOGNOSTIC EVALUATION OF SELECTED MEDICINAL PLANTS:

Each of these plants selected is described in terms of their botanical characteristics and geographical distribution, which provides essential context for their pharmacognostic study in the context of anticancer properties. This type of detailed description aids in the understanding of the variability of the compounds they contain and how these might be influenced by their growing conditions (Radha *et al.*, 2019c).

(i) *Botanical Characteristics of Selected Plants*:

(a) Green Tea (*Camellia sinensis*)

Botanical Characteristics:

1. A small evergreen shrub or tree, growing up to 3–4 meters in height.
2. Leaves are dark green, glossy, and slightly serrated.
3. Small white flowers with a sweet scent, followed by green seed-containing fruits (Radha *et al.*, 2019b).

Geographic Distribution:

1. Originally native to East Asia.
2. Extensively cultivated in China, Japan, India, and other parts of Asia.
3. Thrives in tropical and subtropical climates (Radha *et al.*, 2020).

(b) Turmeric (*Curcuma longa*)

Botanical Characteristics:

1. A perennial, rhizomatous herbaceous plant.
2. Leaves are broad, elongated, and bright green.
3. Produces yellow to orange, cylindrical, aromatic rhizomes (Radha *et al.*, 2021a).

Geographic Distribution:

1. Indigenous to Southeast Asia and the Indian subcontinent.
2. Widely cultivated in India, Bangladesh, Pakistan, Sri Lanka, and Southeast Asia.
3. Requires temperatures between 20°C and 30°C and a considerable amount of annual rainfall to thrive (Radha *et al.*, 2021b).

(c) Grapes (*Vitis vinifera*)

Botanical Characteristics:

1. A deciduous vine which can grow up to 32 meters in length.
2. Leaves are large, lobed, and green, turning red or purple in autumn.

3. Fruit, known as grapes, are borne in clusters, varying in colors like green, red, or purple (Veale *et al.*, 1992).

Geographic Distribution:

1. Native to the Mediterranean region, Central Europe, and Southwestern Asia.
2. Extensively cultivated in Europe, America, and parts of Asia.
3. Prefers temperate climates, with well-drained soils and sufficient sun exposure (Anesini and Perez, 1993).

(d) Garlic (*Allium sativum*)

Botanical Characteristics:

1. A bulbous perennial plant, growing up to 1 meter in height.
2. Leaves are flat, long, and narrow.
3. Produces hermaphrodite flowers; however, bulbils are often more commonly produced (Cox, 1990).

Geographic Distribution:

1. Native to Central Asia and northeastern Iran.
2. Cultivated worldwide, particularly in China, India, South Korea, Egypt, and Russia.
3. Adaptable to a wide range of climates, from temperate to tropical (Cox and Balick, 1994).

(ii) *Phytochemical components known to exhibit anticancer properties*:

Table 4 illustrates the phytochemical components which possess anticancer properties.

MECHANISMS OF ACTION

A detailed exploration of how medicinal plants or their constituents act against Oral Squamous Cell Carcinoma (OSCC) at the molecular and cellular levels involves understanding the complex interactions between phytochemicals and various cellular pathways. The action of medicinal plants and their constituents against OSCC at the molecular and cellular levels is multifaceted, involving a combination of mechanisms that work together to inhibit tumor growth, induce cancer cell death, and enhance the body's natural defenses. Understanding these mechanisms is crucial for developing targeted therapies that effectively utilize the anticancer potential of these natural compounds (Manandhar, 1987; Nair and Shastry, 1988; Tanira *et al.*, 1994; El and Karakaya, 2004).

These interactions can inhibit cancer progression, induce cell death, or enhance the efficacy of conventional treatments. Here is an in-depth look into these mechanisms:

1. *Induction of Apoptosis*:

Triggering Cell Death: Many plant-derived compounds can induce apoptosis, the programmed cell death, in cancer cells. This is often achieved by activating caspases, a family of enzymes that play a vital role in apoptosis.

Mitochondrial Pathways: Some phytochemicals cause the release of cytochrome c from mitochondria, leading to apoptosis. This mechanism involves the disruption of the mitochondrial membrane potential, which is crucial for cell survival (Isbrucker and Burdock, 2006).

2. *Cell Cycle Arrest*:

Inhibiting Cell Proliferation: Certain compounds can halt the cell cycle at specific checkpoints (G0/G1, S, or G2/M phase), preventing cancer cells from dividing and proliferating.

Targeting Cyclins and CDKs: These compounds may modulate the levels of cyclins and cyclin-dependent kinases (CDKs), which are essential for the progression of the cell cycle (Nair *et al.*, 1996).

3. *Inhibition of Angiogenesis*:

Preventing New Blood Vessel Formation: Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis. Phytochemicals can inhibit this process, thereby starving the tumor of nutrients and oxygen.

Downregulation of Pro-Angiogenic Factors: This

Table 4: Phytochemical Components

Plant	Phytochemical Components	Anticancer Properties
Green Tea (*Camellia sinensis*)	Catechins (e.g., epigallocatechin gallate), Flavonoids, Polyphenols	Antioxidant activity, inhibition of cell proliferation, induction of apoptosis in cancer cells.
Turmeric (*Curcuma longa*)	Curcumin, Turmerones, Curcuminoids	Anti-inflammatory, inhibits cell proliferation, induces apoptosis, inhibits angiogenesis.
Grapes (*Vitis vinifera*)	Resveratrol, Flavonoids, Proanthocyanidins	Antioxidant activity, inhibits cancer cell growth, induces apoptosis, anti-inflammatory effects.
Garlic (*Allium sativum*)	Allicin, Sulfur Compounds, Diallyl trisulfide	Inhibits cancer cell proliferation, induces apoptosis, anti-microbial, detoxifying enzymes activation (Baohong,1985).

includes reducing the expression of vascular endothelial growth factor (VEGF) and other angiogenic cytokines (Balasinor *et al.*, 2007).

4. *Modulating Immune Response*:

Enhancing Immune Surveillance: Some plant compounds can strengthen the body's immune response against cancer cells. They may increase the activity of natural killer cells, macrophages, and cytotoxic T lymphocytes.

Reducing Immunosuppression: They can also counteract the immunosuppressive environment often created by tumors, allowing the immune system to target and destroy cancer cells more effectively (Caceres *et al.*, 1991).

5. *Epigenetic Alterations*:

Occurrence of DNA Methylation and Histone Modification, certain phytochemicals can cause epigenetic modifications, such as changes in DNA methylation patterns and histone acetylation, affecting gene expression in cancer cells (Vlietinck *et al.*, 1995).

6. *Inhibiting Metastasis*:

Preventing Cancer Spread: By affecting adhesion molecules and matrix metalloproteinases (MMPs), these compounds can inhibit the invasion and metastasis of cancer cells.

Altering Cell Signaling Pathways: They can modulate signaling pathways like the MAPK, PI3K/Akt, and Wnt/β-catenin pathways, which are often implicated in the metastatic process (Dimayuga and Garcia, 1991).

7. *Enhancing Efficacy of Chemotherapy*:

Some phytochemicals can enhance the efficacy of chemotherapy drugs, either by sensitizing cancer cells to these drugs or by protecting normal cells from their toxic effects.

8. *Detoxification Enzymes Activation*:

Activation of Phase I and II enzymes can lead to the detoxification of carcinogens, reducing the risk of cancer development or progression.

9. *Reactive Oxygen Species (ROS) Modulation*:

While some compounds induce oxidative stress in cancer cells, leading to cell death, others can decrease ROS levels, protecting normal cells from oxidative damage (Mukherjee and Wahile, 2006).

SAFETY, EFFICACY AND REGULATORY CONSIDERATIONS

The considerations of safety, efficacy, and regulatory compliance are critical. The integration of medicinal plants into cancer treatment, particularly for Oral Squamous Cell Carcinoma, requires a balanced approach that rigorously addresses safety, efficacy, and regulatory requirements. Ensuring patient safety, proving the effectiveness of treatments, and adhering to regulatory guidelines are all critical steps in bringing these traditional remedies into modern medical practice. As research progresses, these considerations will guide the responsible and effective use of medicinal plants in oncology (Devasagayam and Sainis, 2002; Rajkumar *et al.*, 2003; Cooper, 2008a,b; Mashelkar, 2008; Joshi *et al.*, 2011; Sanda *et al.*, 2011; Swaminathan *et al.*, 2011; Sharma *et al.*, 2012; Rajkovic *et al.*, 2023).

These aspects are essential for ensuring that the use of medicinal plants in cancer treatment is both beneficial and safe for patients. Here is a detailed look into each of these considerations:

1. Safety

Toxicity Assessment: It is crucial to conduct comprehensive toxicity studies on medicinal plants and their extracts. This includes acute, sub-acute, and chronic toxicity testing, as well as genotoxicity assessments.

Side Effects and Adverse Reactions: Identifying potential side effects and adverse reactions is necessary. This should include investigations into potential herb-drug interactions, especially for patients undergoing conventional cancer treatments (Regassa *et al.*, 2022).

Quality Control: Ensuring the purity and quality of plant extracts is paramount. This involves screening for contaminants such as heavy metals, pesticides, and microbial contamination.

Dosage and Administration: Proper dosage guidelines need to be established, as the therapeutic window for many natural compounds can be narrow. Overdosing or underdosing can lead to ineffectiveness or toxicity (Mo *et al.*, 2016; Reddy *et al.*, 2020).

2. Efficacy

Clinical Trials: Rigorous clinical trials are required to establish the efficacy of medicinal plants in treating OSCC. These should include well-designed phase I, II, and III trials.

Standardization of Extracts: There must be a focus on standardizing the extraction processes to ensure consistent and repeatable efficacy in clinical use.

Mechanisms of Action: Understanding the exact mechanisms through which these plants exert anticancer effects is necessary for determining efficacy. This can be achieved through in-depth pharmacological studies.

Comparative Studies: Comparing the efficacy of these medicinal plants with existing conventional treatments can help in positioning them within the current treatment landscape (Kharat and Kharat, 2019; Kumavath *et al.*, 2021).

3. Regulatory Considerations

Compliance with Regulations: Medicinal plants and their derivatives must comply with the regulatory standards set by health authorities like the FDA, EMA, or other national bodies.

Approval Processes: Navigating the approval process for new drugs derived from plants can be challenging. It requires a thorough demonstration of both safety and efficacy.

Intellectual Property: Issues surrounding patents and intellectual property rights, especially when dealing with traditional knowledge, need careful handling.

Labeling and Marketing: Accurate labeling, including information on ingredients, dosage, and warnings, is essential. Marketing claims must be substantiated by scientific evidence (Tian *et al.*, 2018; Wang *et al.*, 2020).

CHALLENGES AND FUTURE DIRECTIONS

(i) *Identification of gaps in current research*:

In the context of the article several gaps in current research can be identified. These gaps highlight areas where further investigation is needed to fully harness the potential of medicinal plants in treating OSCC (Nunez, 2001).

(a) Lack of Comprehensive Clinical Trials: While there is significant laboratory (*in vitro* and *in vivo*) evidence of the anticancer properties of many medicinal plants, there is a notable gap in clinical trial data. These trials are crucial for determining the efficacy and safety of these plant-derived compounds in humans.

(b) Inadequate Understanding of Mechanisms: While some phytochemicals have been studied for their mechanisms of action against cancer cells, there is still a limited understanding of how these compounds work synergistically and their interactions with conventional cancer treatments.

(c) Variability in Plant Composition: The phytochemical composition of plants can vary greatly depending on geographical location, cultivation methods, and processing techniques. This variability can affect the reproducibility and standardization of research findings.

(d) Optimization of Extraction and Formulation: There is a need for more research on the optimization of extraction methods and formulation techniques to maximize the therapeutic potential of these plant compounds while minimizing any adverse effects.

(e) Lack of Standardized Dosage Guidelines: The absence of standardized dosage guidelines for medicinal plant extracts or compounds is a significant gap. Without these guidelines, it becomes challenging to compare study results or to use these compounds in clinical settings (Porichi *et al.*, 2009; Mateen *et al.*, 2010; Li Yvonne *et al.*, 2011; Crowley *et al.*, 2016; Lu *et al.*, 2018; Sferrazza *et al.*, 2020; Carlberg *et al.*, 2021).

(f) Insufficient Data on Long-term Effects: There is a lack of long-term studies on the use of medicinal plant extracts or compounds, which is necessary to understand their long-term efficacy and safety.

(g) Interactions with Other Drugs: The interactions between phytochemicals and conventional chemotherapy or other medications used by cancer patients are not well-understood. This area requires more research to ensure safe and effective combined treatment regimens.

(h) Limited Focus on Multi-Targeted Therapies: While many studies focus on the effects of single compounds, cancer treatment often requires a multi-targeted approach. The synergistic effects of combining different plant extracts or compounds with conventional therapies need more exploration.

(i) Genetic and Epigenetic Factors: The influence of genetic and epigenetic factors on the efficacy of phytochemicals in treating OSCC is not well studied. Personalized medicine approaches considering these factors could significantly advance the field.

(j) Ethnopharmacological Approaches: There is a gap in integrating ethnopharmacological knowledge with modern scientific approaches. Traditional knowledge can provide valuable insights into effective plant-based treatments that have been overlooked in contemporary research (Geyikoglu *et al.*, 2017; Alagawany *et al.*, 2020; Szechyńska-Hebda *et al.*, 2022; Arul Jothi *et al.*, 2023; Wen *et al.*, 2023).

Addressing these gaps through rigorous scientific research is essential to fully realize the potential of medicinal plants in the treatment of Oral Squamous Cell Carcinoma, paving the way for more effective, natural, and holistic cancer therapies (He *et al.*, 2017).

(ii) *Challenges in integrating traditional medicine with modern oncology practices*:

Integrating traditional medicine, especially the use of medicinal plants, with modern oncology practices presents multiple challenges. These challenges arise from differences in methodologies, cultural beliefs, scientific validation, and regulatory frameworks. Understanding and addressing these challenges is crucial for the effective and safe integration of these diverse treatment modalities. Here are some key challenges:

1. Scientific Validation and Evidence-Based Practice:

Modern medicine relies heavily on evidence-based practices, requiring rigorous scientific validation through clinical trials and research studies. Many traditional medicines, however, are based on historical and empirical evidence, lacking the extensive research data required to meet modern medical standards.

There is often a lack of controlled, randomized clinical trials to prove the efficacy and safety of traditional medicinal practices (Hu *et al.*, 2022).

2. Standardization and Quality Control:

Traditional medicinal products, particularly those derived from plants, often face challenges in standardization of active ingredients. The concentration of bioactive compounds can vary significantly depending on factors like plant species, growing conditions, and preparation methods.

Ensuring consistent quality and potency in each dose is a challenge, which is critical for their acceptance and integration into conventional medicine (Wani *et al.*, 2023).

3. Regulatory and Safety Concerns:

The regulatory frameworks governing the approval and use of traditional medicines are often less stringent or standardized compared to conventional medicines. This can lead to concerns regarding the safety, efficacy, and quality of these products.

Potential adverse effects, drug-herb interactions, and contraindications with conventional cancer therapies are areas of concern (Peng *et al.*, 2022).

4. Cultural and Philosophical Differences:

Traditional medicine often encompasses holistic approaches, focusing on the balance of physical, emotional, and spiritual health. In contrast, modern medicine primarily adopts a more reductionist and disease-focused approach.

Reconciling these differing philosophies and integrating them into a cohesive treatment plan can be challenging (Iakimova *et al.*, 2020).

5. Lack of Trained Professionals:

There is often a lack of practitioners who are adequately trained in both traditional and modern medical practices, making it difficult to effectively integrate these approaches.

Training and education programs that encompass both paradigms are required to bridge this gap (Samtiya *et al.*, 2021).

6. Communication and Acceptance:

Effective communication between practitioners of traditional medicine and modern oncology is essential for integration but is often lacking.

Skepticism and bias among both practitioners and patients can hinder the acceptance and integration of traditional methods in mainstream oncology (Nouri *et al.*, 2020).

7. Research and Funding Limitations:

Research in traditional medicine, particularly in the field of oncology, is often underfunded compared to conventional drug research.

There is a need for more robust research methodologies tailored to assess traditional treatments, which may not fit into the conventional models of drug testing (Singh *et al.*, 2018).

8. Intellectual Property and Ethical Concerns:

Issues of intellectual property rights, benefit-sharing, and ethical considerations in the use of traditional knowledge and natural resources are complex and need careful navigation.

Addressing these challenges requires a multidisciplinary approach, incorporating scientific rigor, respect for traditional knowledge, regulatory reforms, and educational initiatives. Collaborative efforts between traditional medicine practitioners, oncologists, researchers, and policymakers are essential to develop a framework for the safe, effective, and integrated use of traditional and modern oncology practices (Mitchell *et al.*, 2021).

(iii) *Potential future research directions, including genomics and bioinformatics approaches*:

There are several potential future research directions that can be explored, particularly leveraging the advancements in genomics and bioinformatics. These approaches could significantly enhance our understanding of how natural compounds interact with cancer cells and help in developing more effective treatments. Here are some of the key future research directions:

1. Genomic Profiling of OSCC: Comprehensive genomic profiling of OSCC can help identify specific genetic mutations and pathways involved in the disease. This knowledge can guide the selection of medicinal plants or their compounds that target these specific pathways (Herdiana *et al.*, 2022).

2. Bioinformatics in Compound Identification: Utilizing bioinformatics tools to analyze large datasets can aid in the identification of new bioactive compounds in medicinal plants. These tools can predict the pharmacological properties, toxicity, and potential interactions of these compounds (Yang *et al.*, 2020).

3. Molecular Docking and Drug Design: Implementing molecular docking studies can provide insights into how phytochemicals interact at the molecular level with various targets in cancer cells. This can assist in the design of more effective and targeted drug candidates (Annaji *et al.*, 2021).

4. Gene Expression Studies: Investigating the impact of medicinal plant compounds on gene expression in OSCC cells can reveal the mechanisms through which these compounds exert their anticancer effects. Techniques like RNA sequencing can be particularly informative (Sezgin-Bayindir *et al.*, 2021).

5. Systems Biology Approaches: Employing systems biology to understand the complex interactions between natural compounds and biological pathways in cancer. This holistic approach can uncover synergistic effects of various phytochemicals and their impact on cancer networks (Khalil *et al.*, 2020).

6. Personalized Medicine: Integrating genomic data of patients with OSCC with pharmacognostic data can pave the way for personalized medicine approaches. This could involve tailoring specific medicinal plant treatments based on individual genetic profiles (WHO, 2001).

7. Pharmacogenomics: Pharmacogenomic studies can identify how genetic variations in individuals affect their response to certain phytochemicals. This could help predict efficacy and reduce adverse effects (Bannerman *et al.*, 1983).

8. *In Silico* Modelling and Simulation: Advanced *in silico* models and simulation techniques can be used to predict the behavior of phytochemicals in biological systems. This approach can save time and resources in early-stage drug discovery (Eisenberg *et al.*, 1998).

9. Integration of Traditional Knowledge: Digitization and analysis of traditional medicinal knowledge using bioinformatics tools can uncover new insights and validate the use of certain plants in cancer treatment (Dev, 1997).

10. Collaborative Research Platforms: Developing collaborative platforms that bring together pharmacognosists, geneticists, bioinformaticians, and oncologists. Such platforms can facilitate the sharing of data and insights, accelerating the pace of discovery.

By incorporating these advanced research approaches, future studies can enhance the understanding of the anticancer potential of medicinal plants and translate this knowledge into practical therapeutic strategies for treating Oral Squamous Cell Carcinoma (Schulz *et al.*, 1997; Fitzloff *et al.*, 1998; Monmaney , 1998; Constantine and Karchesy, 1998; Awang *et al.*, 1999; Dev, 1999; WHO, 2000; Rees and Weil, 2001).

Conclusion

The research identified and assessed several medicinal plants, such as green tea, turmeric, grapes, and garlic, which possess bioactive compounds with potential anticancer properties.

These findings emphasize the pharmacological potential of natural products in combating oral squamous cell carcinoma. The phytochemical analysis revealed various active constituents, including catechins, curcuminoids, resveratrol, and allicin, which demonstrated a range of anticancer activities, such as antioxidant properties, apoptosis induction, cell proliferation inhibition, and anti-inflammatory effects. The diversity of mechanisms of action suggests that these plants could be crucial in developing multifaceted therapeutic strategies against OSCC. The significant therapeutic potential of these plants as standalone treatments and synergistic agents alongside conventional cancer therapies. Their ability to target various cancer pathways and potentially reduce the side effects of standard chemotherapy presents a promising avenue for integrative cancer treatment. The findings provide a foundation for future research, including in-depth pharmacological studies, clinical trials, and exploration of the synergistic effects of these phytochemicals with existing cancer treatments. The highlighted plants and their compounds could pave the way for novel drug development in the fight against OSCC. It reaffirms the need for continued exploration of natural resources as a source for new, effective, and less toxic therapeutic options.

In conclusion, the pharmacognostic evaluation of these medicinal plants opens up new horizons in the quest for effective and safer treatments for Oral Squamous Cell Carcinoma, highlighting the invaluable role of nature's pharmacy in addressing one of the major health challenges of our times.

References

Abad MJ, Bedoya LM and Bermejo P. (2013) Essential oils from the Asteraceae family active against multidrug-resistant bacteria. In: Fighting Multidrug Resistance with Herbal Extracts, Essential Oils and Their Components, (eds.) Rai M.K. and Kon K.V., Academic Press, San Diego, CA, USA, pp. 205-221.

Alagawany M, Elnesr SS, Farag MR, Tiwari R, Yatoo MI, Karthik K, Michalak I and Dhama K. (2020) Nutritional significance of amino acids, vitamins and minerals as nutraceuticals in poultry production and health-- A comprehensive review. Vet Q. 41: 1-29.

Ammon HP and Wahl MA. (1991) Pharmacology of *Curcuma longa*. Planta Med. 57: 1-7.

Anesini C and Perez C. (1993) Screening of plants used in Argentine folk medicine for antimicrobial activity. J Ethnopharmacol. 39(2):119-128.

Annaji M, Poudel I, Boddu SHS, Arnold RD, Tiwari AK and Babu RJ. (2021) Resveratrol-loaded nanomedicines for cancer applications. Cancer Rep. 4: e1353.

Arul Jothi KN, Kumaran K, Senthil S, Nidhu AB, Munaff N, Janitri VB, Kirubakaran R, Singh SK, Gupt G, Dua K and Krishnan A. (2022) Implications of reactive oxygen species in lung cancer and exploiting it for therapeutic interventions. Med Oncol. 40(1): 43.

Awang DV, Yat PN, Arnason JT, Lu ZZ, Fitzloff JF, Fong H, Hall T and Blumenthal M. (1999) The American Botanical Council's program of evaluation of "ginseng" products on the North American market. InInternational Ginseng Conference.

Balasinor N, Bhan A, Paradkar NS, Shaikh A, Nandedkar TD, Bhutani KK and Roy-Chaudhury M. (2007) Postnatal development and reproductive performance of F_1 progeny exposed *in utero* to an ayurvedic contraceptive: Pippaliyadi yoga. J Ethnopharmacol. 109(3): 406-411.

Bannerman R, Burton J and Chen WC. (1983) Traditional Medicine and Health Care Coverage. Geneva, Switzerland, World Health Organization.

Baohong JI. (1985) Drug resistance in leprosy-- a review. Leprosy Rev. 56(4): 265-278.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68: 394-424.

Caceres A, Cabrera O, Morales O, Mollinedo P and Mendia P. (1991) Pharmacological properties of *Moringa oleifera*. 1: Preliminary screening for antimicrobial activity. J Ethnopharmacol. 33(3): 213-216.

Carlberg C and Velleuer E. (2021) Cancer Biology: How Science Works. Springer, pp. 292.

Cheng H. (1995) Advanced Textbook on Traditional Chinese Medicine and Pharmacology. New World Press; Beijing, China.

Choudhari AS, Mandave PC, Deshpande M, Ranjekar P and Prakash O. (2020) Phytochemicals in cancer treatment: From preclinical studies to clinical practice. Front Pharmacol. 10: 1614.

Constantine GH and Karchesy J. (1998) Variations in hypericin concentrations in *Hypericum perforatum* L. and commercial products. Pharm Biol. 36: 365-367.

Cooper EL. (2008a) Ayurveda is embraced by eCAM. Evidence-Based Complem Altern Med. 5(1): 1-2.

Cooper EL. (2008b) Ayurveda and eCAM: a closer connection. Evidence-Based Complem Altern Med. 5(2): 121-122.

Cox PA. (1990) Ciba Foundation Symposium 154. Chichester, UK: John Wiley & Sons.

Cox PA and Balick MJ. (1994) The ethnobotanical approach to drug discovery. Sci American 270(6): 82-87.

Crowley Lisa C, Brooke JM, Adrian PS and Waterhouse Nigel J. (2016) Quantitation of apoptosis and necrosis by annexin V binding, propidium iodide uptake, and flow cytometry. Cold Spring Harb Protoc. 2016(11): pdb-prot087288.

Dev S. (1997) Ethnotherapeutics and modern drug development:the potential of Ayurveda. Cur Sci. 73: 909-928.

Dev S. (1999) Ancient-modern concordance in Ayurvedic plants: some examples. Environ Health Persp. 107: 783-789.

Devasagayam TPA and Sainis KB. (2002) Immune system and antioxidants, especially those derived from Indian medicinal plants. Indian J Exp Biol. 40: 639-655.

Dimayuga RE and Garcia SK. (1991) Antimicrobial screening of medicinal plants from Baja California Sur, Mexico. J Ethnopharmacol. 31(2):181-192.

Efferth T. (2005) Mechanistic perspectives for 1, 2, 4-trioxanes in anti-cancer therapy. Drug Resist. Updat. 8: 85-97.

Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M and Kessler RC. (1998) Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 280(18): 1569-1575.

El SN and Karakaya S. (2004) Radical scavenging and iron-chelating activities of some greens used as traditional dishes in Mediterranean diet. Int J Food Sci Nutrit. 55(1): 67-74.

Faried A, Kurnia D, Faried L, Usman N, Miyazaki T, Kato H and Kuwano H. (2007) Anticancer effects of gallic acid isolated from Indonesian herbal medicine, *Phaleria macrocarpa* (Scheff.) Boerl, on human cancer cell lines. Int J Oncol. 30: 605-613.

Fattovich G, Stroffolini T, Zagni I and Donato F. (2004) Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology127: S35-S50.

Fitzloff JF, Yat P, Lu ZZ, Awng DV, Arnason JT, van Breemen RB, Blumenthal M and Fong HH. (1998) Perspectives on the quality assurance of ginseng products in North America. In: Proceedings of the Ginseng Society Conference 1998, The Korean Society of Ginseng, pp. 138-145.

Geyikoglu F, Emir M, Colak S, Koc K, Turkez H, Bakir M, Hosseinigouzdagani M, Cerig S, Keles ON and Ozek NS. (2017) Effect of oleuropein against chemotherapy drug-induced histological changes, oxidative stress, and DNA damages in rat kidney injury. J Food Drug Anal. 25: 447-459.

Ghorani-Azam A, Sepahi S, Riahi-Zanjani B, Ghamsari AA, Mohajeri SA and Balali-Mood M. (2018) Plant toxins and acute medicinal plant poisoning in children: A systematic literature review. J Res Med Sci. 23: 26.

He L, He T, Farrar S, Ji L, Liu T and Ma X. (2017) Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen species. Cell Physiol Biochem. 44: 532-553.

Hema KN, Smitha T, Sheethal HS and Mirnalini SA. (2017) Epigenetics in oral squamous cell carcinoma. J Oral Maxillofac Pathol. 21: 252.

Herdiana Y, Wathoni N, Shamsuddin S and Muchtaridi M. (2022) Scale-up polymeric-based nanoparticles drug delivery systems: Development and challenges. OpenNano 7: 100048.

Hoare A, Soto C, Rojas-Celis V and Bravo D. (2019) Chronic inflammation as a link between periodontitis and carcinogenesis. Mediat Inflamm. 2019: 1029857.

Hu J, Pan D, Li G, Chen K and Hu X. (2022) Regulation of programmed cell death by Brd4. Cell Death Dis. 13: 1059.

Hu Y and Davies GE. (2010) Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. Fitoterapia 81: 358-366.

Iakimova ET, Yordanova ZP, Cristescu SM, Harren FFM and Woltering EJ. (2020) Cell death associated release of volatile organic sulphur compounds with antioxidant properties in chemical-challenged tobacco BY-2 suspension cultured cells. J Plant Physiol. 251: 153223.

Inoue M, Suzuki R, Koide T, Sakaguchi N, Ogihara Y and Yabu Y. (1994) Antioxidant, gallic acid, induces apoptosis in HL-60RG cells. Biochem Biophys Res Commun. 204: 898-904.

Irani S. (2020) New insights into oral cancer--Risk factors and prevention: A review of literature. Int J Prev Med. 11: 202.

Isbrucker RA and Burdock GA. (2006) Risk and safety assessment on the consumption of Licorice root (*Glycyrrhiza* sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regulatory Toxicol Pharmacol. 46(3): 167-192.

Jain S, Dwivedi J, Jain PK, Satpathy S and Patra A. (2016) Medicinal plants for treatment of cancer: A brief review. Pharmacogn J. 8: 87-102.

Joshi K, Ghodke Y and Patwardhan B. (2011) Traditional medicine to modern pharmacogenomics: Ayurveda Prakriti type and CYP2C19 gene polymorphism associated with the metabolic variability. Evidence-Based Complem Altern Med. 2011: 249528.

Karpuz M, Silindir-Gunay M and Ozer AY. (2018) Current and future approaches for effective cancer imaging and treatment. Cancer Biother Radiopharm. 33: 39-51.

Khalil I, Yehye WA, Etxeberria AE, Alhadi AA, Dezfooli SM, Julkapli NBM, Basirun WJ and Seyfoddin A. (2020) Nanoantioxidants: Recent trends in antioxidant delivery applications. Antioxidants 9: 24.

Kharat Kiran R and Kharat Arun S. (2019) The *Calotropis gigantea* methanolic extract induces apoptosis in human breast carcinoma cells. Iran J Med Sci. 44(6): 483.

Koehn FE and Carter GT. (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov. 4: 206-220.

Kumar M, Changan S, Tomar M, Prajapati U, Saurabh V, Hasan M, Sasi M, Maheshwari C, Singh S, Dhumal S, Radha, Thakur M, Punia S, Satankar V, Amarowicz R and Mekhemar M. (2021b) Custard apple (*Annona squamosa* L.) leaves: Nutritional composition, phytochemical profile, and health-promoting biological activities. Biomolecules 11(5): 614.

Kumar M, Potkule J, Patil S, Mageshwaran V, Radha SV, Berwal MK, Mahapatra A, Saxena S, Ashtaputre N and Souza CD. (2021d) Evaluation of detoxified cottonseed protein isolate for application as food supplement. Toxin Rev. 41(2): 412-419.

Kumar M, Tomar M, Punia S, Grasso S, Arrutia F, Choudhary J, Singh S, Verma P, Mahapatra A, Patil S., Radha, Dhumal S, Potkule J, Saxena S and Amarowicz R. (2021c) Cottonseed: A sustainable contributor to global protein requirements. Trends Food Sci Technol. 111: 100-113.

Kumar M, Tomar M, Saurabh V, Sasi M, Punia S, Potkule J, Maheshwari C, Changan S, Radha, Bhushan B, Singh S, Anitha T, Alajil O, Satankar V, Dhumal S, Amarowicz R, Kaur C, Sharifi-Rad J and Kennedy JF. (2021a) Delineating the inherent functional descriptors and biofunctionalities of pectic polysaccharides. Carbohydr Polym. 269: 118319.

Kumavath R, Paul S, Pavithran H, Paul MK, Ghosh P, Barh D and Azevedo V. (2021) Emergence of cardiac glycosides as potential drugs: Current and future scope for cancer therapeutics. Biomolecules 11(9): 1275.

Li Yvonne Y, An Jianghong and Jones Steven JM. (2011) A computational approach to finding novel targets for existing drugs. PLoS Comput Biol. 7(9): e1002139.

Liu F and Ng T. (2000) Antioxidative and free radical scavenging activities of selected medicinal herbs. Life Sci. 66: 725-735.

Llovet JM. (2005) Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 40: 225-235.

Lu H, Zou WX, Meng JC, Hu J and Tan RX. (2000) New bioactive metabolites produced by *Colletotrichum* sp., an endophytic fungus in *Artemisia annua*. Plant Sci. 151: 67-73.

Lu J, Wang Z, Cao J, Chen Y and Dong Y. (2018) A novel and compact review on the role of oxidative stress in female reproduction. Reprod Biol Endocrinol. 16: 80.

Manandhar NP. (1987) Traditional medicinal plants used by Tribals of Lamjung District, Nepal. Int J Crude Drug Res. 25(4): 236-240.

Mashelkar RA. (2008) Second world Ayurveda congress (theme: Ayurveda for the future)—inaugural address: part III. Evidence-Based Complem Altern Med. 5(4): 367-369.

Mateen S, Tyagi A, Agarwal C, Singh RP and Agarwal R. (2010) Silibinin inhibits human non-small cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators. Mol Carcinog. 49: 247-258.

Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA and Langer R. (2021) Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 20: 101-124.

Mo EP, Zhang RR, Xu J, Zhang H, Wang XX, Tan QT, Liu FL, Jiang RW and Cai SH. (2016) Calotropin from *Asclepias curasavica* induces cell cycle arrest and apoptosis in cisplatin-resistant lung cancer cells. Biochem Biophys Res Commun. 478(2): 710-715.

Monmaney T. (1998) Remedy's U.S. Sales zoom, but quality control lags. The Los Angeles Times. August 31, 1998: A1-A10.

Mukherjee PK and Wahile A. (2006) Integrated approaches towards drug development from

Ayurveda and other Indian system of medicines. J Ethnopharmacol. 103(1): 25-35.

Nair MP and Shastry ARK, (1987) Red Data Book of Indian Plants. Calcutta, India: Botanical Survey of India.

Nair S, Nagar R and Gupta R. (1996) Dietary anti-oxidant phenolics and flavonoids in coronary heart disease. Indian Heart J. 48: 545.

Nobili S, Lippi D, Witort E, Donnini M, Bausi L, Mini E and Capaccioli S. (2009) Natural compounds for cancer treatment and prevention. Pharmacol Res. 59: 365-378.

Nouri Z, Fakhri S, Nouri K, Wallace CE, Farzaei MH and Bishayee A. (2020) Targeting multiple signaling pathways in cancer: The rutin therapeutic approach. Cancers 12: 2276.

Nunez R. (2001) DNA measurement and cell cycle analysis by flow cytometry. Curr Issues Mol Biol. 3(3): 67-70.

Pal SK and Shukla Y. (2003) Herbal medicine: Current status and the future. Asian Pac J Cancer Prev. 4: 281-288.

Peng F, Liao M, Qin R, Zhu S, Peng C, Fu L, Chen Y and Han B. (2022) Regulated cell death (RCD) in cancer: Key pathways and targeted therapies. Signal Transduct Target Ther. 7: 286.

Porichi O, Nikolaidou ME, Apostolaki A, Tserkezoglou A, Arnogiannaki N, Kassanos D, Margaritis L and Panotopoulou E. (2009) BCL-2, BAX and P53 expression profiles in endometrial carcinoma as studied by real-time PCR and immunohisto-chemistry. Anticancer Res. 29(10): 3977-3982.

Radha, Janjua S, Srivastava S and Negi V. (2020) Ethnobotanical study of medicinal plants used in shikari devi wildlife sanctuary of Himachal Pradesh, India. Med Plants 12: 666-673.

Radha, Kumar M, Puri S, Pundir A, Bangar SP, Changan S, Choudhary P, Parameswari E, Alhariri A, Samota MK, Damale RD, Singh S, Berwal MK, Dhumal S, Bhoite AG, Senapathy M, Sharma A, Bhushan B and Mekhemar M. (2021b) Evaluation of Nutritional, Phytochemical, and Mineral Composition of Selected Medicinal Plants for Therapeutic Uses from Cold Desert of Western Himalaya. Plants (Basel) 10(7): 1429.

Radha, Puri S and Kumar V. (2019) Phytochemical screening of medicinal plants used by tribal migratory shepherds in Western Himalaya. Ann Biol. 35:11-14.

Radha, Puri S and Pundir A. (2019b) Review on ethnomedicinal plant: *Trillium govanianum* Wall. Ex D. Don. Int J Theor Appl Sci. 11: 4-9.

Radha, Puri S, Chandel K, Pundir A, Thakur MS, Chauhan B, Simer K, Dhiman N, Shivani Thakur YS and Kumar S. (2019c) Diversity of ethnomedicinal plants in Churdhar Wildlife Sanctuary of district Sirmour of Himachal Pradesh, India. J Appl Pharm Sci. 9: 48-53.

Radha, Chauhan P, Puri S, Thakur M, Rathour S, Sharma AK and Pundir A. (2021a) A study of wild medicinal plants used in Nargu Wildlife Sanctuary of district Mandi in Himachal Pradesh, India. J Appl Pharm Sci. 11: 135-144.

Rajkovic J, Novakovic R, Grujic-Milanovic J, Ydyrys A, Ablaikhanova N, Calina D, Sharifi-Rad J and Al-Omari B. (20230 An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer. Front Pharmacol. 14: 1160616.

Rajkumar T, Sridhar H, Balaram P, Vaccarella S, Gajalakshmi V, Nandakumar A, Ramdas K, Jayshree R, Muñoz N, Herrero R, Franceschi S and Weiderpass E. (2003) Oral cancer in Southern India: the influence of body size, diet, infections and sexual practices. Eur J Cancer Prev.12(2): 135-143.

Reddy D, Kumavath R, Barh D, Azevedo V and Ghosh P. (2020) Anticancer and antiviral properties of cardiac glycosides: a review to explore the mechanism of actions. Molecules 25(16): 3596.

Rees L and Weil A. (2001) Integrated medicine imbues orthodox medicine in the values of complementary medicine. British Med J. 322: 119-120.

Regassa H, Sourirajan A, Kumar V, Pandey S, Kumar D and Dev K. (2022) A review of medicinal plants of the Himalayas with anti-proliferative activity for the treatment of various cancers. Cancers 14(16): 3898.

Ruan WJ, Lai MD and Zhou JG. (2006) Anticancer effects of Chinese herbal medicine, science or myth? J Zhejiang Univ Sci B. 7: 1006-1014.

Ryu JH, Lee SJ, Kim MJ, Shin JH, Kang SK, Cho KM and Sung NJ. (2011) Antioxidant and anticancer activities of *Artemisia annua* L. and determination of functional compounds. J Korean Soc Food Sci Nutr. 40: 509-516.

Saklani A and Kutty SK. (2008) Plant-derived compounds in clinical trials. Drug Discov Today 13:161-171.

Samtiya M, Aluko RE, Dhewa T and Moreno-Rojas JM. (2021) Potential health benefits of plant food-derived bioactive components: An overview. Foods 10: 839.

Sanda KA, Grema HA, Geidam YA and Bukar-Kolo YM. (2011) Pharmacological aspects of *Psidium guajava*: an update. Int J Pharmacol. 2011: 1–9.

Schulz V, Hubner WD and Ploch M. (1997) Clinical trials with phytopharmacological agents. Phytomedicine 4: 379-387.

Sezgin-Bayindir Z, Losada-Barreiro S, Bravo-Díaz C, Sova

M, Kristl J and Saso L. (2021) Nanotechnology-based drug delivery to improve the therapeutic benefits of NRF2 modulators in cancer therapy. Antioxidants 10: 685.

Sferrazza G, Corti M, Brusotti G, Pierimarchi P, Temporini C, Serafino A and Calleri E. (2020) Nature-derived compounds modulating Wnt/β-catenin pathway: a preventive and therapeutic opportunity in neoplastic diseases. Acta Pharm Sin B. 10(10): 1814-1834.

Sharma R, Thakur GS, Sanodiya BS, savita A, Pandey M, Sharma A and Bisen PS. (2012) Therapeutic potential of *Calotropis procera*: a giant milkweed. ISOR J Pharm Biol Sci. 4(2): 42-57.

Shehab NG, Mahdy A, Khan SA and Noureddin SM. (2011) Chemical constituents and biological activities of *Fagonia indica* Burm F. Res J Med Plant 5: 531-546.

Singh K, Bhori M, Arfat Y, Bhat G and Marar T. (2018) Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity-- Exploring the armoury of obscurity. Saudi Pharm J. 26: 177-190.

Singh RP, Prakash S, Bhatia R, Negi M, Singh J, Bishnoi M and Kondepudi KK. (2020) Generation of structurally diverse pectin oligosaccharides having prebiotic attributes. Food Hydrocoll. 108: 10.

Sohi KK, Mittal N, Hundal MK and Khanduja KL. (2003) Gallic acid, an antioxidant, exhibits antiapoptotic potential in normal human lymphocytes: A Bcl-2 independent mechanism. J Nutr Sci Vitaminol (Tokyo) 49: 221-227.

Sun J, Chu YF, Wu X and Liu RH. Antioxidant and antiproliferative activities of common fruits. J Agric Food Chem. 50: 7449-7454.

Sun Y, Liu N, Guan X, Wu H, Sun Z and Zeng H. (2016) Immunosuppression induced by chronic inflammation and the progression to oral squamous cell carcinoma. Mediat Inflamm. 2016: 5715719.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F. (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71: 209-249.

Swaminathan R, Shanta V, Ferlay J, Balasubramanian S, Bray F and Sankaranarayanan R. (2011) Trends in cancer incidence in Chennai city (1982–2006) and statewide predictions of future burden in Tamil Nadu (2007–16). Natl Med J India 24(2): 72-77.

Szechyńska-Hebda M, Ghalami RZ, Kamran M, Van Breusegem F and Karpiński S. (2022) To be or not to be? Are reactive oxygen species, antioxidants, and stress signalling universal determinants of life or death? Cells 11: 4105.

Tan RX, Zheng W and Tang H. (1998) Biologically active substances from the genus *Artemisia*. Planta Med. 64: 295-302.

Tang J, Feng Y, Tsao S, Wang N, Curtain R and Wang Y. (2009) Berberine and Coptidis rhizoma as novel antineoplastic agents: A review of traditional use and biomedical investigations. J Ethnopharmacol. 126: 5-17.

Tanira MOM, Bashir AK, Dib R, Goodwin CS, Wasfi IA and Banna NR. (1994) Antimicrobial and phytochemical screening of medicinal plants of the United Arab Emirates. J Ethnopharmacol. 41(3): 201-205.

Taraphdar AK, Roy M and Bhattacharya R. (2001) Natural products as inducers of apoptosis: Implication for cancer therapy and prevention. Curr Sci. 2001: 1387-1396.

Thakur MK and Waske S. (2018) Study of medicinal plants used by local herbal healers in south block of Seoni District (M.P.). Int J Theor Appl Sci. 10: 95-99.

Tian L, Xie XH and Zhu ZH. (2018) Calotropin regulates the apoptosis of non-small cell cancer by regulating the cytotoxic T-lymphocyte associated antigen 4-mediated TGF-β/ERK signaling pathway. Mol Med Rep. 17(6): 7683-7691.

Trease G. and Evans W. (1983) Textbook of Pharmacognosy. Balliere, London, UK.

Veale DJH, Furman KI and Oliver DW. (1992) South African traditional herbal medicines used during pregnancy and childbirth. J Ethnopharmacol. 36(3):185-191.

Vlietinck AJ, Van Hoof L, Totté J, Lasure A, Vanden Berghe D, Rwangabo PC and Mvukiyumwami J. (1995) Screening of hundred Rwandese medicinal plants for antimicrobial and antiviral properties. J Ethnopharmacol. 46(1): 31-47.

Wang CZ, Calway T and Yuan CS. (2012) Herbal medicines as adjuvants for cancer therapeutics. Am J Chin Med. 40: 657-669.

Wang Z, Zhang L, Wan Z, He Y, Huang H, Xiang H, Wu X, Zhang K, Liu Y, Goodin S, Du Z and Zheng X. 92020) Atorvastatin and caffeine in combination regulates apoptosis, migration, invasion and tumorspheres of prostate cancer cells. Pathol Oncol Res. 26(1): 209-216.

Wani AK, Akhtar N, Mir TUG, Singh R, Jha PK, Mallik SK, Sinha S, Tripathi SK, Jain A, Jha A, Devkota HP and Prakash A. (2023) Targeting Apoptotic Pathway of Cancer Cells with Phytochemicals and Plant-Based Nanomaterials. Biomolecules 13(2): 194.

Wen ZH, Kuo HM, Shih PC, Hsu LC, Chuang JMJ, Chen NF, Sun HW, Liu HT, Sung CS and Chen WF. (20230

Isoaaptamine increases ROS levels causing autophagy and mitochondria-mediated apoptosis in glioblastoma multiforme cells. Biomed. Pharmacother. 160: 114359.

World Health Organization (2000) Traditional and modern medicine-- Harmonizing the two approaches. Manila, Philippines: WHO, Regional Office for the Western Pacific..

World Health Organization (2001) Guidelines for methodologies on research and evaluation of traditional medicine. Geneva, Switzerland: WHO.

Xie W, Gu D, Li J, Cui K and Zhang Y. (2011) Effects and action mechanisms of berberine and *Rhizoma coptidis* on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. PLoS One 2011: 6:e24520.

Yang B, Dong Y, Wang F and Zhang Y. (2020) Nanoformulations to enhance the bioavailability and physiological functions of polyphenols. Molecules 25: 4613.

Yasmine G and Elnaaj A. (2017) Global incidence and risk factors of oral cancer. Harefuah 156: 645-649.

Yin J, Zhang H and Ye J. (2008) Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord. Drug Targets 8: 99-111.